We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$8.02B
AUM Growth
+$201M
(+2.6%)
Cap. Flow
-$89M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
19.81%
Holding
867
New
76
Increased
308
Reduced
302
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$48.8M |
| 2 |
Procter & Gamble
PG
|
+$24.6M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$23.6M |
| 4 |
Keysight
KEYS
|
+$23.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$21.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$46.5M |
| 2 |
ExxonMobil
XOM
|
+$36.6M |
| 3 |
GG
Goldcorp Inc
GG
|
+$24.9M |
| 4 |
Walt Disney
DIS
|
+$23.8M |
| 5 |
NAVG
Navigators Group Inc
NAVG
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.16% |
| 2 | Technology | 16.87% |
| 3 | Financials | 10.38% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Communication Services | 7.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
AngioDynamics
ANGO
$562M
| $1.37M | 0.02% |
70,000
| – | – |
|
577
KLA
KLAC
$275B
| $1.37M | 0.02% |
116,100
+22,900
| +25% | +$265K |
|
578
Hormel Foods
HRL
$13.9B
| $1.34M | 0.02% |
33,270
+1,187
| +4% | +$48.1K |
|
579
Artivion
AORT
$1.23B
| $1.34M | 0.02% |
45,000
| – | – |
|
580
Amplify Cybersecurity ETF
HACK
$2.63B
| $1.34M | 0.02% |
33,825
+2,940
| +10% | +$117K |
|
581
TC Energy
TRP
$73.5B
| $1.32M | 0.02% |
26,700
-109,010
| -80% | -$5.23M |
|
582
Chipotle Mexican Grill
CMG
$40.8B
| $1.3M | 0.02% |
89,200
+10,400
| +13% | +$147K |
|
583
Wabtec
WAB
$51.1B
| $1.29M | 0.02% |
18,110
+5,519
| +44% | +$391K |
|
584
BioLife Solutions
BLFS
$1.46B
| $1.28M | 0.02% |
76,000
| – | – |
|
585
Warner Bros
WBD
$64.6B
| $1.27M | 0.02% |
41,724
+4,120
| +11% | +$120K |
|
|
PPLI
586
People Inc
PPLI
$3.1B
| $1.27M | 0.02% |
32,834
+5,875
| +22% | +$234K |
|
|
LITS
587
Lite Strategy Inc
LITS
$33.6M
| $1.27M | 0.02% |
25,500
| – | – |
|
588
Cardinal Health
CAH
$53.4B
| $1.26M | 0.02% |
26,971
-8,405
| -24% | -$388K |
|
589
Pentair
PNR
$10.2B
| $1.26M | 0.02% |
34
+5
| +17% | +$190 |
|
590
Southwest Gas
SWX
$6.74B
| $1.26M | 0.02% |
14,135
-28,595
| -67% | -$2.43M |
|
591
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| – | – |
-1,100
| Closed | -$317K |
|
|
IMGN
592
DELISTED
Immunogen Inc
IMGN
| $1.25M | 0.02% |
579,210
-575,511
| -50% | -$1.36M |
|
|
CIT
593
DELISTED
CIT Group Inc.
CIT
| $1.25M | 0.02% |
23,890
-2,084
| -8% | -$105K |
|
594
Regency Centers
REG
$15B
| $1.22M | 0.02% |
18,374
+1,729
| +10% | +$116K |
|
|
STML
595
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.22M | 0.02% |
+80,000
| New | +$1.16M |
|
596
Canadian Pacific Kansas City
CP
$82B
| $1.22M | 0.02% |
25,885
-14,935
| -37% | -$667K |
|
|
VER
597
DELISTED
VEREIT, Inc.
VER
| $1.21M | 0.02% |
27,054
+2,468
| +10% | +$107K |
|
598
Cincinnati Financial
CINF
$28.3B
| $1.21M | 0.02% |
11,716
+893
| +8% | +$85.7K |
|
599
International Flavors & Fragrances
IFF
$19.4B
| $1.19M | 0.01% |
8,229
-583
| -7% | -$81K |
|
600
Copart
CPRT
$25.9B
| $1.18M | 0.01% |
63,652
+6,232
| +11% | +$107K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2019 Portfolio in Review
As of Q2 2019, Candriam SCA held 867 positions worth $8.02B, up 2.6% from $7.82B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA's Q2 2019 filing shows 76 new, 308 increased, 302 reduced and 63 closed positions. Its largest new stake was Total System Services, Inc.: 112,342 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $46.5M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q2 2019 buy was Total System Services, Inc.: 112,342 shares worth $14.3M.
- Candriam SCA added most to Vertex Pharmaceuticals in Q2 2019, an estimated $48.8M increase.
- Candriam SCA's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $46.5M.
- Candriam SCA fully exited Goldcorp Inc in Q2 2019, selling an estimated $24.9M.
- Candriam SCA's ten largest holdings make up 20% of its $8.02B portfolio in Q2 2019.
- Candriam SCA opened 76 new positions and closed 63 in Q2 2019.
- Candriam SCA's portfolio value rose 2.6% quarter-over-quarter to $8.02B.
Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.